Ivenix,  Inc.  Closes  Initial  Tranche  of  $50  Million  Financing  to  Accelerate  Growth  of  Transformative  Infusion  System  

 

Amesbury,  MA,  March  21,  2017  —Ivenix,  Inc.,  a  medical  technology  company  developing  the  next  generation  infusion  system,  today  announced  it  has  closed  on  the  first  tranche  of  a  $50  million  round  of  equity  financing  for  its  new  technology  platform,  the  Ivenix  Infusion  System.    This  funding  will  allow  the  company  to  pursue  FDA  clearance  and  quickly  expand  its  team  for  commercial  launch.    The  remaining  tranches  will  be  funded  upon  the  attainment  of  regulatory  milestones  and  satisfaction  of  other  conditions.  

The  financing  was  led  by  two  new  undisclosed  investors,  as  well  as  participation  from  existing  investors  F-­‐Prime  Capital  Partners  and  WuXi  Healthcare  Ventures,  among  others.    

“A  number  of  factors  are  fueling  investor  interest  in  Ivenix,  including  the  lack  of  innovation  in  the  market,  and  the  incidence  of  errors  in  infusion  administration,”  said  Stuart  Randle,  Chief  Executive  Officer  of  Ivenix.    “Our  system  represents  a  complete  redesign  of  the  infusion  pump  from  the  ground  up,  with  fully  integrated  technology  to  support  interoperability  and  improved  safety  and  performance.”    

The  Ivenix  Infusion  System  brings  the  power  of  an  advanced  information  technology  platform  to  provide  immediate,  secure  access  to  patient-­‐specific  infusion  and  pump  management  information,  available  at  the  place  and  time  decisions  are  made.    An  intuitive  user  interface  guides  users  through  interactions  with  the  pump,  much  like  a  smartphone.    Combined  with  a  fundamentally  new  pump  technology  designed  for  accuracy  and  efficiency,  the  system  takes  a  comprehensive  approach  to  the  market  challenges  of  large  volume  infusion  delivery  and  management.  

“The  demand  for  an  innovative  infusion  system  in  healthcare  is  evident,  and  we  are  proud  to  support  Ivenix  as  the  trailblazer  working  to  bring  a  truly  revolutionary  solution  to  this  underserved  market,”  said  Ketan  Patel,  MD,  partner  with  F-­‐Prime.    “Moreover,  infusion  pumps  represent  a  $6  billion  global  market  and  offer  significant  opportunities  for  a  high-­‐performance  infusion  system  that  can  meet  the  challenges  of  healthcare  today,  while  providing  the  infrastructure  to  support  the  emerging  technologies  of  tomorrow.”    

“The  Ivenix  team  is  committed  to  patient  safety  and  to  taking  the  lead  in  bringing  large  volume  infusion  delivery  into  the  modern  world  of  connected  healthcare,”  Randle  added.    “The  Ivenix  Infusion  System  is  poised  to  transform  infusion  therapy.    We  are  looking  forward  to  building  our  commercial  team  and  bringing  the  system  to  market  following  FDA  clearance.”    

 

 

About  Ivenix  

Ivenix,  Inc.  is  a  medical  technology  company  with  a  vision  to  transform  infusion  therapy  in  every  care  setting.    Technology  within  the  infusion  pump  category  has  been  slow  to  evolve  despite  an  increase  in  the  complexity  of  drug  dosing  regimens,  demand  for  hospital  EMR  integration,  and  persistent  patient  safety  issues.  

Ivenix  is  focused  on  bringing  its  first  solution  to  market,  a  new  and  innovative  infusion  system  for  hospitals.    The  company  is  headquartered  in  Amesbury,  Massachusetts.    For  more  information,  please  visit  www.ivenix.com.  

The  U.S.  FDA  has  not  yet  reviewed  the  Ivenix  Infusion  System.  

Media  Contact:  Molly  McDougall  HealthFlash  Marketing  203-­‐431-­‐4000  molly@healthflashmarketing.com